Intrahepatic cholangiocarcinoma (ICC) is a rare yet deadly form of liver cancer. Beyond surgical resection which can only be applied to a minority of the patients, there is no effective treatment for ICC. There is a clear urgent need to develop novel treatment strategies against this deadly malignancy. Recently, we and others demonstrated the critical role of Notch and Hippo signaling cascades in ICC pathogenesis. For the Notch pathway, we found that Notch receptors, including Notch1 and Notch2 are highly expressed in majorities of human ICC samples. Treatment of ?-secreatase inhibitors (GSI) or inhibition of Notch using molecular approaches is able to repress human ICC cell proliferation and induce apoptosis in vitro. Mechanistically, we showed that Notch functions to regulate MAPK signaling. For the Hippo pathway, we uncovered a strong and ubiquitous activation of Yap and TAZ, the transcriptional activators downstream of Hippo tumor suppressor kinases, in human ICC as well as mouse ICC samples. In vitro, upregulation of Hippo cascade by overexpressing Lats2 or blocking Yap/TAZ activity via dominant negative form of TEAD2 (dnTEAD2) strongly inhibited ICC cell growth. Similar results were obtained when Yap or TAZ expression was silenced in human ICC cells. Furthermore, overexpression of Lats2 or dnTEAD2 strongly delayed ICC development induced by loss of Pten and TP53 tumor suppressors (sgPten/sgP53). In vivo, using hydrodynamic transfection, we discovered that activated forms of Yap (YapS127A) or TAZ (TAZS89A) synergized with activated AKT signaling to promote ICC development. ICC driven by activated AKT and Yap/TAZ depends on Notch as blocking canonical Notch strongly inhibited ICC development in mice. Based on these preliminary studies, we hypothesize that the canonical Notch pathway medicated via Notch1 and/or Notch2 is required for ICC development via modulating MAPK cascade. We further hypothesize that Yap and TAZ, the major transcriptional activators downstream of Hippo tumor suppressor kinases, have overlapping yet distinct roles in ICC development and elucidation of these roles will be critical to exploit the modulation of this pathway for translational implications.
Two aims are proposed to test these hypotheses.
In Aim 1, we will elucidate the canonical Notch signaling cascade in ICC development.
In Aim 2, we will define the functional contribution of Yap and TAZ in regulating ICC pathogenesis. Altogether, in the proposed application, we will apply in vitro mechanistic studies in combination with sophisticated mouse genetic approaches to uncover the molecular mechanisms underlying Notch and Hippo cascades in regulating ICC tumorigenesis. The study will likely provide strong evidence to support the development and application of anti-Notch and/or Yap/TAZ based therapeutics for ICC treatment. Based on the quality of preliminary data and availability of all necessary reagents for balanced in vitro and in vivo studies, we feel confident that we will be able to address the significance of these biological pathways in liver pathology to eventually devise better understanding and hence therapies for ICC.

Public Health Relevance

Cholangiocarcinoma is a deadly disease, lacking any effective treatment options. The application seeks to understand the functional roles of Notch and Hippo signaling cascades during cholangiocarcinoma development. The study is likely to provide new insight into the molecular genetics of cholangiocarcinoma and strong evidence to support the development of therapeutics targeting Notch or Hippo pathway as novel treatment strategies for this deadly malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA190606-05
Application #
9894769
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Watson, Joanna M
Project Start
2016-04-05
Project End
2021-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Zhang, Shanshan; Wang, Jingxiao; Wang, Haichuan et al. (2018) Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. Am J Pathol 188:995-1006
Liu, Xianqiong; Song, Xinhua; Zhang, Jie et al. (2018) Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma. Cancer Med 7:6170-6181
Wang, Jingxiao; Dong, Mingjie; Xu, Zhong et al. (2018) Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. Oncogene 37:3229-3242
Dong, Mingjie; Liu, Xianqiong; Evert, Katja et al. (2018) Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death Dis 9:31
Cigliano, Antonio; Wang, Chunmei; Pilo, Maria G et al. (2017) Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice. Oncotarget 8:54149-54159
Zhang, Shanshan; Song, Xinhua; Cao, Dan et al. (2017) Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol 67:1194-1203
Che, L; Fan, B; Pilo, M G et al. (2016) Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans. Oncogenesis 5:e274